WO2026114292 - STABLE PHARMACEUTICAL COMPOSITION OF ANTI-RANKL ANTIBODY
National phase entry is expected:
Publication Number
WO/2026/114292
Publication Date
04.06.2026
International Application No.
PCT/CN2025/137985
International Filing Date
27.11.2025
Title **
[English]
STABLE PHARMACEUTICAL COMPOSITION OF ANTI-RANKL ANTIBODY
[French]
COMPOSITION PHARMACEUTIQUE STABLE D'ANTICORPS ANTI-RANKL
[Chinese]
稳定的抗RANKL抗体的药物组合物
Applicants **
QILU PHARMACEUTICAL CO., LTD.
Inventors
LI, Na
ZHANG, Le
AN, Zhenming
SUN, Lixia
ZHOU, Xin
LIU, Fang
XI, Yaya
WANG, Qingmin
ZHANG, Yingkuan
Priority Data
202411718429.4
27.11.2024
CN
202511734636.3
21.11.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1716 | |
| EPO | Filing, Examination, Granting | 11598 | |
| Japan | Filing, Examination, Granting | 2108 | |
| South Korea | Filing, Examination, Granting | 2025 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,187
Contact Us
Abstract[English]
A stable pharmaceutical composition containing an anti-RANKL antibody, and more specifically, a pharmaceutical composition of denosumab. The composition has ensured stability and reduced insoluble particles in the preparation, which effectively solves the problems in high-concentration antibody preparations with respect to drug manufacturing, storage, transportation, and delivery.[French]
Une composition pharmaceutique stable contenant un anticorps anti-RANKL, et plus spécifiquement, une composition pharmaceutique de dénosumab. La composition présente une stabilité assurée et une réduction des particules insolubles dans la préparation, ce qui résout efficacement les problèmes liés aux préparations d'anticorps à haute concentration en ce qui concerne la fabrication, le stockage, le transport et la livraison du médicament.[Chinese]
一种稳定的含有抗RANKL抗体的药物组合物，更具体地，地舒单抗的药物组合物，其在降低了制剂的不溶性微粒的同时保证了组合物的稳定性，有效解决了高浓度抗体制剂在药物制造、保存运输和药物递送上的问题。